Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer’s disease assessment

Darren M. Weber, Steven W. Taylor, Robert J. Lagier, Jueun C. Kim, Scott M. Goldman, Nigel J. Clarke, David E. Vaillancourt, Ranjan Duara, Karen N. McFarland, Wei-en Wang, Todd E. Golde, Michael K. Racke
doi: https://doi.org/10.1101/2023.12.12.23299878
Darren M. Weber
aQuest Diagnostics Nichols Institute, San Juan Capistrano, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: darren.m.weber{at}questdiagnostics.com
Steven W. Taylor
aQuest Diagnostics Nichols Institute, San Juan Capistrano, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Lagier
aQuest Diagnostics Nichols Institute, San Juan Capistrano, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jueun C. Kim
aQuest Diagnostics Nichols Institute, San Juan Capistrano, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott M. Goldman
aQuest Diagnostics Nichols Institute, San Juan Capistrano, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nigel J. Clarke
aQuest Diagnostics Nichols Institute, San Juan Capistrano, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David E. Vaillancourt
bDepartment of Applied Physiology and Kinesiology, Fixel Institute for Neurological Disorders, and 1Florida ADRC, University of Florida, Gainesville, FL USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ranjan Duara
bDepartment of Applied Physiology and Kinesiology, Fixel Institute for Neurological Disorders, and 1Florida ADRC, University of Florida, Gainesville, FL USA
cWien Center for Alzheimer’s Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, FL USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen N. McFarland
dDepartment of Neurology, Center for Translational Research in Neurodegenerative Disease, 1Florida Alzheimer’s Disease Research Center (ADRC), University of Florida, Gainesville, FL USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei-en Wang
bDepartment of Applied Physiology and Kinesiology, Fixel Institute for Neurological Disorders, and 1Florida ADRC, University of Florida, Gainesville, FL USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Todd E. Golde
dDepartment of Neurology, Center for Translational Research in Neurodegenerative Disease, 1Florida Alzheimer’s Disease Research Center (ADRC), University of Florida, Gainesville, FL USA
eDepartment of Pharmacology and Chemical Biology and Department of Neurology Center for Neurodegenerative Disease, Goizueta Institute Emory Brain Health, Emory University, School of Medicine. Atlanta, GA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael K. Racke
aQuest Diagnostics Nichols Institute, San Juan Capistrano, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

INTRODUCTION Plasma Aβ42/40 ratio can be used to help predict amyloid PET status, but its clinical utility in Alzheimer’s disease (AD) assessment is unclear.

METHODS Aβ42/40 ratio was measured by LC-MS/MS in 250 specimens with associated amyloid PET imaging, diagnosis, and demographic data, and 6,192 consecutive clinical specimens submitted for Aβ42/40 testing.

RESULTS High diagnostic sensitivity and negative predictive value (NPV) for Aβ-PET positivity were observed, consistent with the clinical performance of other plasma LC-MS/MS assays, but with greater separation between Aβ42/40 values for individuals with positive vs negative Aβ-PET results. Assuming a moderate prevalence of Aβ-PET positivity, a cutpoint was identified with 99% NPV, which could help predict that AD is likely not the cause of patients’ cognitive impairment and help reduce PET evaluation by about 40%.

DISCUSSION Using high-throughput plasma Aβ42/40 LC-MS/MS assays can help reduce PET evaluations in patients with low likelihood of AD pathology, allowing for cost savings.

Highlights

  • A new plasma LC-MS/MS assay for the Aβ42/Aβ40 ratio has clinical utility in AD assessment.

  • Performance was assessed using specimens with a moderate prevalence of Aβ-PET positivity.

  • Analysis was extrapolated to 6,192 consecutive clinical specimens submitted for ratio testing.

  • Assay cutpoints were proposed to help suggest clinical management decisions.

  • Based on the assay’s high NPV, costly PET evaluations may be avoided for many individuals.

Systematic Review Aβ42/Aβ40 ratio data were analyzed from 250 ADRC cohort participants and 6,192 plasma specimens submitted for Aβ42/40 ratio testing by LC-MS/MS at Quest Diagnostics.

Interpretation Based on its high NPV, the assay identifies individuals likely to have negative amyloid PET results. Higher discriminatory power and larger fold-changes between PET-positive and negative individuals were observed compared with previous studies. Our “real-world” data set, combined with known performance characteristics, allows us to suggest cutpoints and clinical decisions based on plasma Aβ42/40 ratios.

Future Directions Longitudinal plasma specimens from individuals who convert from PET-negative to positive, or that transition from cognitively normal to MCI and AD, will improve understanding of the prognostic utility of the Aβ42/40 ratio. Using Aβ42/40 ratio alone or combined with other biomarkers, to follow patients with cognitive impairment may yield insights regarding their disease conditions and progression and who may benefit from disease-modifying therapeutics.

Competing Interest Statement

Darren M. Weber, Steven W. Taylor, Robert J. Lagier, Jueun C. Kim, Scott M. Goldman, Nigel J. Clarke, and Michael K. Racke are employees of Quest Diagnostics. All other authors have nothing to disclose.

Clinical Trial

This study is of a new plasma LC-MS/MS assay for the Aβ42/Aβ40 ratio

Funding Statement

Funding for this work was provided by National Institutes of Health (NIH) Center Core Grant P30AG066506 (TEG) and NIH Research Grants R01NS052318 and R01NS075012 (DEV).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Mount Sinai Medical Center IRB, and all participants provided informed consent.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 14, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer’s disease assessment
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer’s disease assessment
Darren M. Weber, Steven W. Taylor, Robert J. Lagier, Jueun C. Kim, Scott M. Goldman, Nigel J. Clarke, David E. Vaillancourt, Ranjan Duara, Karen N. McFarland, Wei-en Wang, Todd E. Golde, Michael K. Racke
medRxiv 2023.12.12.23299878; doi: https://doi.org/10.1101/2023.12.12.23299878
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer’s disease assessment
Darren M. Weber, Steven W. Taylor, Robert J. Lagier, Jueun C. Kim, Scott M. Goldman, Nigel J. Clarke, David E. Vaillancourt, Ranjan Duara, Karen N. McFarland, Wei-en Wang, Todd E. Golde, Michael K. Racke
medRxiv 2023.12.12.23299878; doi: https://doi.org/10.1101/2023.12.12.23299878

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)